Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc.'s Q·Score is 8/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $449.48 is 52% above current price. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ALNY is $449.48, based on ratings from 25 Wall Street analysts. This is 51.8% above the current price of $296.11. Price targets are forward-looking estimates and not guarantees of future performance.

Alnylam Pharmaceuticals, Inc. (ALNY) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 21.2×. The consensus analyst price target of $449.48 is 52% above the current price.

Alnylam Pharmaceuticals, Inc.'s next earnings report is expected on approximately July 30, 2026.

Alnylam Pharmaceuticals, Inc. has a net profit margin of 12.6%, which is solid for most industries. Its gross margin stands at 80.8%, indicating a high-margin business model.

Alnylam Pharmaceuticals, Inc. is reporting strong year-over-year growth of 96.4%.

Alnylam Pharmaceuticals, Inc. has a debt-to-equity ratio of 2.76×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 3.13×, indicating comfortable short-term liquidity.